VF
CLDX icon

Virtu Financial’s Celldex Therapeutics CLDX Stock Holding History

Virtu Financial’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$629K Buy
+19,830
New +$541K 0.03% 490
2024
Q2 		– Sell
-19,644
Closed -$824K – 1381
2024
Q1 		$824K Buy
+19,644
New +$807K 0.06% 271
2019
Q4 		– Sell
-13,993
Closed -$30K – 1481
2019
Q3 		$30K Buy
+13,993
New +$32.4K ﹤0.01% 1252
2019
Q2 		– Sell
-25,826
Closed -$127K – 1494
2019
Q1 		$127K Buy
25,826
+24,826
+2,483% +$131K 0.01% 1091
2018
Q4 		$3K Sell
1,000
-420
-30% -$2.06K ﹤0.01% 1495
2018
Q3 		$10K Sell
1,420
-164
-10% -$1.15K ﹤0.01% 1448
2018
Q2 		$12K Buy
1,584
+816
+106% +$10.9K ﹤0.01% 1895
2018
Q1 		$27K Buy
+768
New +$29.8K ﹤0.01% 1794
2017
Q4 		– Sell
-2,332
Closed -$100K – 2417
2017
Q3 		$100K Buy
+2,332
New +$87.4K 0.01% 2076
2015
Q3 		– Sell
-801
Closed -$303K – 324
2015
Q2 		$303K Buy
+801
New +$318K 0.03% 258

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Virtu Financial's CLDX Position: Q1 2026 in Review

Virtu Financial opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 19,830 shares worth $629K. The stake represents 0.03% of the portfolio and ranks #490 among its holdings. This is a return to the name: Virtu Financial previously reported a position in CLDX as recently as Q1 2024.

Virtu Financial first reported a position in CLDX in Q2 2015 and has held it in 10 quarters since. The position peaked at $824K in Q1 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Virtu Financial held 19,830 shares of Celldex Therapeutics worth $629K as of Q1 2026.
  • Celldex Therapeutics was a new Virtu Financial position in Q1 2026.
  • Celldex Therapeutics made up 0.03% of Virtu Financial's portfolio in Q1 2026, its #490 holding.
  • Virtu Financial first reported a position in Celldex Therapeutics in Q2 2015 and has held it in 10 quarters since.
  • Virtu Financial's Celldex Therapeutics position peaked at $824K in Q1 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.